An Adaptive Phase 2/3 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults and Adolescents With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

被引：0
|
作者：
Dellon, Evan S. [1 ]
Rothenberg, Marc E. [2 ,3 ]
Chehade, Mirna [4 ]
Mortensen, Eric [5 ]
Laws, Elizabeth [6 ]
Maloney, Jennifer [5 ]
Martincova, Renata [6 ]
Paleczny, Heather [5 ]
Glotfelty, Lila [6 ]
Shabbir, Arsalan [5 ]
机构：
[1] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[2] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[4] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Eosinophil Disorders, New York, NY 10029 USA
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Bridgewater, NJ USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1876
引用
收藏
页码：S1392 / S1393
页数：2
相关论文
共 50 条
  • [31] ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: Results after 18 months
    Mistry, Pramod
    Amato, Dominick J.
    Dasouki, Majed
    Packman, Seymour
    Pastores, Gregory M.
    Assouline, Sarit
    Balwani, Manisha
    Ortega, Andres
    Shankar, Suma
    Solano, Maria Helena
    Rossk, Leorah H.
    Angell, Jennifer
    Peterschmitt, M. Judith
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S81 - S82
  • [32] Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months
    Amato, Dominick J.
    Dasouki, Majed
    Packman, Seymour
    Pastores, Gregory M.
    Assouline, Sarit
    Balwani, Manisha
    Mistry, Pramod
    Ortega, Andres
    Shankar, Suma
    Helena Solano, Maria
    Ross, Leorah H.
    Angell, Jennifer
    Peterschmitt, Judith
    BLOOD, 2014, 124 (21)
  • [33] Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study
    Cai, Xiaoling
    Ji, Linong
    Yuan, Mingxia
    Ma, Jianhua
    Bian, Fang
    Li, Sheli
    Pang, Wuyan
    Yan, Shuang
    Zhou, Huimin
    Hou, Minghui
    Li, Wenhui
    Jia, Ying
    Liu, Li
    Ding, Ke
    Xu, Michael
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 51
  • [34] EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2).
    As-Sanie, Sawsan
    Becker, Christian M.
    Johnson, Neil
    Lessey, Bruce Arthur
    Abrao, Mauricio S.
    Brown, Eric L.
    Wilk, Krzysztof
    Ferreira, Juan Camilo Arjona
    Mathur, Vandana
    Li, Yulan
    Warsi, Qurratul Ann
    Wagman, Rachel B.
    Giudice, Linda C.
    FERTILITY AND STERILITY, 2020, 114 (03) : E77 - E77
  • [35] STUDY DESIGN OF A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN ANTAGONIST, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)
    Murakhovskaya, I.
    Fattizzo, B.
    Cueto, D.
    Jouvin, M. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1751 - 1751
  • [36] Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study
    Inoue, Yuichi
    Watanabe, Takeshi
    Takashima, Shuya
    Takase, Takao
    Ishikawa, Kohei
    Kubota, Naoki
    Yardley, Jane
    Moline, Margaret
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2021, 17 (05): : 1067 - 1074
  • [37] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
    Armstrong, A.
    Gooderham, M.
    Warren, R. B.
    Papp, K.
    Strober, B.
    Thaci, D.
    Colston, E.
    Throup, J.
    Kundu, S.
    Banerjee, S.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 795 - 796
  • [38] RATIONALE AND DESIGN OF THE 52-WEEK, RANDOMIZED, PHASE 3, HEAD-TO-HEAD MANDARA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB, A HUMANIZED, ANTI-INTERLEUKIN-5 RECEPTOR. MONOCLONAL ANTIBODY IN REFRACTORY OR RELAPSING EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
    Wechsler, M.
    Merkel, P. A.
    Necander, S.
    Sjo, L. Borjesson
    Duncan, E. A.
    Makulova, N.
    D'angelo, G.
    Chen, R. A.
    Shih, V. H.
    Katial, R.
    Martin, U. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1435 - 1436
  • [39] Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy
    Robinson, Jennifer G.
    Rogers, William J.
    Nedergaard, Bettina S.
    Fialkow, Jonathan
    Neutel, Joel M.
    Ramstad, David
    Somaratne, Ransi
    Legg, Jason C.
    Nelson, Patric
    Scott, Rob
    Wasserman, Scott M.
    Weiss, Robert
    CLINICAL CARDIOLOGY, 2014, 37 (04) : 195 - 203
  • [40] Efficacy and Safety of Seltorexant as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Phase 2b, Randomized, Placebo-Controlled, Parallel-Group, Adaptive Dose-Finding Study
    Savitz, Adam
    Wajs, Ewa
    Zhang, Yun
    Xu, Haiyan
    Etropolski, Mila
    Saoud, Jay
    Luthringer, Remy
    Drevets, Wayne
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 123 - 123
12345